Bedside Transcatheter Patent Ductus Arteriosus Device Occlusion in an Extremely Low Birth Weight Neonate: A Novel Approach in a High-Risk Population
- PMID: 34745665
- PMCID: PMC8566062
- DOI: 10.1155/2021/4716997
Bedside Transcatheter Patent Ductus Arteriosus Device Occlusion in an Extremely Low Birth Weight Neonate: A Novel Approach in a High-Risk Population
Abstract
Extremely low birth weight (ELBW) infants weighing less than 1 kilogram are at a high-risk for delayed patent ductus arteriosus (PDA) closure. Percutaneous PDA closure offers a less invasive approach when compared with surgical PDA closure, which may provide faster recovery times and less transfusion requirements. However, this procedure involves transporting tenuous, unstable patients from the neonatal intensive care unit (NICU) to the catheterization laboratory which introduces many potential risks for the neonate. Performing percutaneous PDA closure at the bedside offers a successful alternative to performing the procedure in the catheterization laboratory and avoiding risk associated with transporting ELBW neonates.
Copyright © 2021 Tiffany M. Pouldar et al.
Conflict of interest statement
Dr. Evan Zahn is a consultant for Abbott and was the national P.I. for the ADOII-AS (Piccolo) Clinical Trial. All other authors declare that they have no conflicts of interest.
References
Publication types
LinkOut - more resources
Full Text Sources
